Details of the Drug Reposition

General Information of This Drug (ID: DMUM7HZ)

• Drug Name: Fluorouracil (DMUM7HZ)
• Synonyms: 5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU
• Therapeutic Class: Immunosuppressive Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

11 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Rectum mucinous adenocarcinoma	DIS75WFS	N.A.	Approved	[1]
Pancreatic adenocarcinoma	DISKHX7S	N.A.	Approved	[1]
Metastasis from malignant tumor of colon	DIS175N9	N.A.	Approved	[1]
Gastric intestinal type adenocarcinoma	DISEO8Y0	N.A.	Approved	[1]
Colon adenocarcinoma	DISDRE0J	N.A.	Approved	[1]
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Approved	[2]
Gastroesophageal junction adenocarcinoma	DISCVPML	2B71	Approved	[1]
Rectal adenocarcinoma	DIS8R9VO	2B92	Approved	[1]
Biliary tract cancer	DISBNYQL	2C17	Approved	[1]
Adenocarcinoma	DIS3IHTY	2D40	Approved	[1]
Esophageal squamous cell carcinoma	DIS5N2GV	2E60.1	Approved	[1]

6 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Neoplasm of esophagus	DISOLKAQ	N.A.	Discontinued in Phase 2	[3]
Diffuse gastric adenocarcinoma	DISTAPUS	N.A.	Discontinued in Phase 2	[4]
Rectal signet ring cell adenocarcinoma	DISORL5H	N.A.	Discontinued in Phase 2	[5]
Esophageal adenocarcinoma	DISODWFP	N.A.	Discontinued in Phase 2	[6]
Colorectal neoplasm	DISR1UCN	N.A.	Discontinued in Phase 2	[7]
Squamous cell carcinoma	DISQVIFL	2B60-2D01	Discontinued in Phase 2	[8]

2 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Cancer of unknown primary site	DISSA12E	N.A.	Discontinued in Phase 1	[9]
Actinic keratosis	DISR1RC5	EK90.0	Discontinued in Phase 1	[10]

4 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Colon mucinous adenocarcinoma	DISXZXEI	N.A.	Investigative	[1]
Gastric cancer	DISXGOUK	2B72	Investigative	[1]
Colon cancer	DISVC52G	2B90.Z	Investigative	[1]
Colorectal cancer	DISNH7P9	2B91.Z	Investigative	[11]

References

• [1] Fluorouracil FDA Label
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
• [4] A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
• [5] Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
• [6] A Folinic Acid Intervention for Autism Spectrum Disorders
• [7] ClinicalTrials.gov (NCT00373581) Effects of Vigabatrin on Cocaine Self-Administration
• [8] Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
• [9] Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
• [10] ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
• [11] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.